---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-017765"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:46:02.110595+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma posts record Q1 revenue of $27.7M, first positive adjusted EBITDA of $1.4M

## Summary
- Record quarterly net revenue of $27.7M, up 26% YoY; Rx segment revenue grew 34% to $18.7M.
- Positive adjusted EBITDA of $1.4M vs. ($4.2M) loss a year ago; net loss narrowed to ($2.9M).
- Indefinitely suspended clinical programs (AR101/enzastaurin), saving over $20M in future study costs.
- Leadership changes: Jarrett Disbrow as Chief Business Officer, Topher Brooke as COO, Ryan Selhorn as EVP Finance.
- Extended interest-only period on Avenue debt to Jan 2024, saving $3M in 2023 principal payments; warrant exercise price reset to $0.43.

## SEC filing metadata
- accession: 0001558370-22-017765
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000155837022017765/0001558370-22-017765-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000155837022017765/aytu-20221114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-017765
- JSON: https://secwatch.observer/filing/0001558370-22-017765.json
- Plain text: https://secwatch.observer/filing/0001558370-22-017765.txt

## Key facts
- Earnings Releases
  AYTU BIOPHARMA, INC reported the first quarter of fiscal year 2023 ended September 30, 2022 results: revenue $27.7 million.
  - Period: the first quarter of fiscal year 2023 ended September 30, 2022
  - Revenue: $27.7 million
  - Result: reported results
  source text: Q1 2023 Commercial Highlights (3 months ending September 30, 2022) · Total net revenue was $27.7 million, a new quarterly record, and an increase of 26% over the $21.9 million in net revenue in the year ago quarter.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000155837022017765/0001558370-22-017765-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.